GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MEI Pharma Inc (NAS:MEIP) » Definitions » E10

MEI Pharma (MEI Pharma) E10 : $-14.25 (As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is MEI Pharma E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

MEI Pharma's adjusted earnings per share data for the three months ended in Dec. 2023 was $-1.660. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-14.25 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average E10 Growth Rate was 22.30% per year. During the past 5 years, the average E10 Growth Rate was 25.20% per year. During the past 10 years, the average E10 Growth Rate was 22.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of MEI Pharma was 28.30% per year. The lowest was 10.70% per year. And the median was 23.95% per year.

As of today (2024-04-28), MEI Pharma's current stock price is $3.05. MEI Pharma's E10 for the quarter that ended in Dec. 2023 was $-14.25. MEI Pharma's Shiller PE Ratio of today is .


MEI Pharma E10 Historical Data

The historical data trend for MEI Pharma's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MEI Pharma E10 Chart

MEI Pharma Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -48.99 -34.98 -24.98 -19.52 -16.44

MEI Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.56 -16.60 -16.44 -14.98 -14.25

Competitive Comparison of MEI Pharma's E10

For the Biotechnology subindustry, MEI Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MEI Pharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MEI Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where MEI Pharma's Shiller PE Ratio falls into.



MEI Pharma E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, MEI Pharma's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-1.66/129.4194*129.4194
=-1.660

Current CPI (Dec. 2023) = 129.4194.

MEI Pharma Quarterly Data

per share eps CPI Adj_EPS
201403 -6.800 99.695 -8.827
201406 -8.000 100.560 -10.296
201409 -8.400 100.428 -10.825
201412 -7.800 99.070 -10.190
201503 -5.400 99.621 -7.015
201506 -2.600 100.684 -3.342
201509 -2.600 100.392 -3.352
201512 -3.000 99.792 -3.891
201603 -3.200 100.470 -4.122
201606 -3.400 101.688 -4.327
201609 -2.400 101.861 -3.049
201612 6.400 101.863 8.131
201703 -0.400 102.862 -0.503
201706 -2.400 103.349 -3.005
201709 -4.800 104.136 -5.965
201712 -3.200 104.011 -3.982
201803 -3.200 105.290 -3.933
201806 -8.200 106.317 -9.982
201809 -4.200 106.507 -5.104
201812 -3.000 105.998 -3.663
201903 -4.800 107.251 -5.792
201906 -3.000 108.070 -3.593
201909 -0.800 108.329 -0.956
201912 -5.200 108.420 -6.207
202003 -0.800 108.902 -0.951
202006 -4.000 108.767 -4.759
202009 -2.200 109.815 -2.593
202012 -2.600 109.897 -3.062
202103 -4.600 111.754 -5.327
202106 -2.600 114.631 -2.935
202109 -3.600 115.734 -4.026
202112 -2.800 117.630 -3.081
202203 -1.310 121.301 -1.398
202206 -2.440 125.017 -2.526
202209 -2.490 125.227 -2.573
202212 1.540 125.222 1.592
202303 -2.320 127.348 -2.358
202306 -1.510 128.729 -1.518
202309 8.460 129.860 8.431
202312 -1.660 129.419 -1.660

Add all the adjusted EPS together and divide 10 will get our e10.


MEI Pharma  (NAS:MEIP) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


MEI Pharma E10 Related Terms

Thank you for viewing the detailed overview of MEI Pharma's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


MEI Pharma (MEI Pharma) Business Description

Traded in Other Exchanges
N/A
Address
11455 El Camino Real, Suite 250, San Diego, CA, USA, 92130
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
Executives
Taheer Datoo director 181 BAY STREET, SUITE 4200, TORONTO A6 M5J 2T3
James P Flynn director 41 HARRIS CT, DANVILLE CA 94526
Sujay Kango director 1028 CHAMBERS COURT, BRIDGEWATER NJ 08807
Richard G Ghalie officer: Chief Medical Officer C/O FAVRILLE, INC, 10445 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Bruce Ross Winson 10 percent owner 5950 BERKSHIRE LANE, SUITE 510, DALLAS TX 75225
Anson Funds Management Lp 10 percent owner 16000 DALLAS PARKWAY, SUITE 800, DALLAS TX 75248
Anson Management Gp Llc 10 percent owner 16000 DALLAS PARKWAY, SUITE 800, DALLAS TX 75248
Anson Advisors Inc. 10 percent owner 155 UNIVERSITY AVENUE, SUITE 207, TORONTO A6 M5H 3B7
Funicular Funds, Lp 10 percent owner 2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Amin Nathoo 10 percent owner 155 UNIVERSITY AVENUE, SUITE 207, TORONTO Z4 M5H 3B7
Moez Kassam 10 percent owner 111 PETER STREET, SUITE 904, TORONTO A6 M5V2H1
Justin J. File officer: CFO and Corporate Secretary C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Jacob Ma-weaver 10 percent owner 2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Cable Car Capital Llc 10 percent owner 2261 MARKET STREET #4307, SAN FRANCISCO CA 94114
Baltic Charles V. Iii director C/O MARSHALL EDWARDS, INC., 11975 EL CAMINO REAL, SUITE 101, SAN DIEGO CA 92130